Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study

Dragana Milojkovic, Nicholas C P Cross, Sahra Ali, Jenny Byrne, Gavin Campbell, Fiona L Dignan, Mark Drummond, Brian Huntly, Scott Marshall, Mary Frances McMullin, Pratap Neelakantan, Manoj Raghavan, Muttuswamy Sivakumaran, Jane Tighe, Farooq Wandroo, Fenella Willis, Fiona Glen, Louise Fildes, Sarah J Collington, Jacqueline RyanRichard E Clark, Adam J Mead

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Management of chronic myeloid leukaemia (CML) has recently undergone dramatic changes, prompting the European LeukemiaNet (ELN) to issue recommendations in 2013; however, it remains unclear whether real-world CML management is consistent with these goals. We report results of UK TARGET CML, a retrospective observational study of 257 patients with chronic-phase CML who had been prescribed a first-line TKI between 2013 and 2017, most of whom received first-line imatinib (n = 203). Although 44% of patients required ≥1 change of TKI, these real-world data revealed that molecular assessments were frequently missed, 23% of patients with ELN-defined treatment failure did not switch TKI, and kinase domain mutation analysis was performed in only 49% of patients who switched TKI for resistance. Major molecular response (MMR; BCR-ABL1IS ≤0·1%) and deep molecular response (DMR; BCR-ABL1IS ≤0·01%) were observed in 50% and 29%, respectively, of patients treated with first-line imatinib, and 63% and 54%, respectively, receiving a second-generation TKI first line. MMR and DMR were also observed in 77% and 44% of evaluable patients with ≥13 months follow-up, receiving a second-generation TKI second line. We found little evidence that cardiovascular risk factors were considered during TKI management. These findings highlight key areas for improvement in providing optimal care to patients with CML.

Original languageEnglish
JournalBritish Journal of Haematology
Early online date24 May 2020
DOIs
Publication statusEarly online date - 24 May 2020
Externally publishedYes

Bibliographical note

© 2020 British Society for Haematology and John Wiley & Sons Ltd.

Fingerprint Dive into the research topics of 'Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study'. Together they form a unique fingerprint.

Cite this